Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621943 · ClinicalTrials.gov registry record · NA
Umbilical Cord Milking in Non-Vigorous Infants Developmental Followup (MINVIFU)
A NA study of Neurodevelopmental Abnormality, sponsored by Sharp HealthCare.
- Completed
- Registry status
- NA
- Development phase
- 1,207
- Enrollment target
- 10
- Study locations
NCT03621943: Completed NA study of Neurodevelopmental Abnormality, sponsored by Sharp HealthCare.
NCT03621943 is a NA study of Neurodevelopmental Abnormality that has completed, run by Sharp HealthCare. The registered enrollment target is 1,207 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03621943, a NA study of Neurodevelopmental Abnormality, has completed, sponsored by Sharp HealthCare.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,207 participants
- Enrollment target
- 10
- Study locations
Study Summary
A sub-study to evaluate longer-term developmental outcomes in non-vigorous term and near-term newborns who receive umbilical cord milking in comparison to those who undergo early cord clamping at delivery.
Primary Outcome
Neurodevelopmental Outcome at 2 Years of Age defined as overall and domain scores on the Ages and Stages, third edition. Questionnaire. Minimum score of 0 and maximum score of 60 per domain. Scores from 5 subscales are summed to obtain a total score. 5 domains assessed include communication, gross motor, fine motor, problem solving, personal social with a total minimum score of 0 and maximum score of 300. Higher scores indicate a lower risk of developmental delays or conditions
Conditions Studied
Interventions
- PROCEDURE Umbilical Cord Milking
- PROCEDURE Early Cord Clamping
Study Locations (10)
California
- University of California, Davis - Davis
- Loma Linda Medical Center - Loma Linda
- Sharp Grossmont Hospital - San Diego
- Sharp Mary Birch Hospital for Women and Newborns - San Diego
District of Columbia
- George Washington University - Washington D.C.
Oregon
- Providence St. Vincent Medical Center - Portland
Utah
- University of Utah/IMH - Salt Lake City
Alberta
- University of Alberta - Edmonton
New Brunswick
- Dalhousie University - Dalhousie
Other
- Poznan University of Medical Science - Poznan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,207 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2023-09-26 |
| Phase | NA |
What the finished NCT03621943 record still lists
NCT03621943 is an interventional study that assigns participants to a tested intervention. Its 1,207 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Neurodevelopmental Abnormality appearing as the primary indexed condition, and to 2 interventions - of which Umbilical Cord Milking is the first listed.
NCT03621943 lists 10 locations in 7 states (California, District of Columbia, Oregon).
Frequently Asked Questions
What is clinical trial NCT03621943 about?
NCT03621943 is a clinical study titled "Umbilical Cord Milking in Non-Vigorous Infants Developmental Followup (MINVIFU)". A sub-study to evaluate longer-term developmental outcomes in non-vigorous term and near-term newborns who receive umbilical cord milking in comparison to those who undergo early cord clamping at delivery.
What is the current status of trial NCT03621943?
This trial is currently completed. It is a NA study. The enrollment target is 1,207 participants. The study started on 2019-01-07. Estimated completion is 2023-09-26.
What conditions does trial NCT03621943 study?
This clinical trial studies the following conditions: Neurodevelopmental Abnormality.
What interventions are being tested in trial NCT03621943?
The interventions under investigation include: Umbilical Cord Milking (PROCEDURE), Early Cord Clamping (PROCEDURE).
Who is sponsoring clinical trial NCT03621943?
This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03621943 being conducted?
This trial has 10 study locations across California, District of Columbia, Oregon, Utah, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurodevelopmental Abnormality
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03621943's enrollment target sits among peer trials
1,207 83rd of 2000 higher than 1,918 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI